All In Biotech

Drug Trial Radar · NCT02079246

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Aug 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,463

Actual

Start

Apr 7, 2014

Primary completion

Jul 6, 2017

Study completion Jul 6, 2017

Sponsor

Lead sponsor
H. Lundbeck A/SIndustry
Sponsor type
Industry
First posted
Mar 5, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the long-term safety and tolerability of idalopirdine (Lu AE58054) as adjunctive therapy to donepezil in patients with mild-moderate Alzheimer's Disease (AD).

Conditions

  • Alzheimer's Disease

Interventions

  • Idalopirdine 60 mgDrug

    once daily, encapsulated tablets, orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Treatment Emergent Adverse Events (TEAEs) in the OLEXTime frame: Baseline II (start of OLEX, week 0) to end of OLEX (week 28)
  2. Number of TEAEs in the OLEX-MEMTime frame: From Baseline III (start of OLEX-MEM, Week 28) to end of OLEX-MEM (Week 52)

Locations

258 sites in 27 countries. Site status is shown where the registry gives one.

  • US027

    Birmingham, Alabama

  • US012

    Phoenix, Arizona

  • US338

    Phoenix, Arizona

  • US024

    Little Rock, Arkansas

  • US351

    Carlsbad, California

  • US346

    Costa Mesa, California

  • US327

    Fullerton, California

  • US023

    Imperial, California

  • US045

    Long Beach, California

  • US307

    Redlands, California

  • US058

    San Francisco, California

  • US018

    Santa Ana, California

  • US301

    Santa Rosa, California

  • US021

    Bradenton, Florida

  • US050

    Brooksville, Florida

  • US308

    Delray Beach, Florida

  • US320

    Hallandale, Florida

  • US347

    Hialeah, Florida

  • US340

    Lake Worth, Florida

  • US303

    Miami, Florida

  • US313

    Miami, Florida

  • US345

    Orange City, Florida

  • US019

    Orlando, Florida

  • US309

    Palm Beach Gardens, Florida

  • US038

    Port Charlotte, Florida

  • US302

    Sunrise, Florida

  • US304

    Atlanta, Georgia

  • US360

    Augusta, Georgia

  • US048

    Kailua, Hawaii

  • US030

    Chicago, Illinois

  • US040

    Indianapolis, Indiana

  • US334

    Lake Charles, Louisiana

  • US036

    Freeport, Maine

  • US344

    Boston, Massachusetts

  • US035

    Kalamazoo, Michigan

  • US310

    Saint Paul, Minnesota

  • US041

    Flowood, Mississippi

  • US321

    Hattiesburg, Mississippi

  • US339

    Paterson, New Jersey

  • US046

    Princeton, New Jersey

Showing 40 of 258 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.